30 April 2026
30 April 2026
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
This deal falls under Teva’s wider strategy to prioritise strategic, financially diligent deals around de-risked, differentiated, late-stage assets.
Regeneron’s total revenue increased 19% year-on-year to $3.6bn from $3.02bn.
With publication of the first JCA report imminent, procedural and methodological challenges persist.
The PRIME status for RTx-015 was granted based on preliminary Phase I/II safety and efficacy clinical data.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
